Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CL-NK-003 in Advanced Pancreatic Cancer
NCT07425483Phase 1Recruiting
- Sponsor
- Changhai Hospital
- Start
- Feb 2026
- Primary completion
- Dec 2026
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CL-NK-003 in pancreatic cancer (PC), sponsored by Changhai Hospital. Primary endpoints: Dose-limiting toxicity at 42 days, Treatment-emergent adverse event and treatment-emergent serious adverse event at 42 days and 3 more. Started Feb 2026; status: recruiting.
02
Drugs
CL-NK-003
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07425483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07425483.